Evidence map›Paper›PMID 38634933›Full record

ArticleParasitology research2024

Differential susceptibility of Onchocerca ochengi adult male worms to flubendazole in gerbils and hamsters.

Glory Enjong Mbah, Rene Bilingwe Ayiseh, Elvis Monya, Emmanuel Menang Ndi, Fabrice Ngoh Njotu, Tessy-Koko Kulu, Judy Sakanari, Sara Lustigman, Fidelis Cho-Ngwa

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Glory Enjong MbahANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea, Cameroon.
Rene Bilingwe AyisehANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea, Cameroon. rbilingwe@yahoo.com.
Elvis MonyaANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea, Cameroon.
Emmanuel Menang NdiANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea, Cameroon.
Fabrice Ngoh NjotuANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea, Cameroon.
Tessy-Koko KuluANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea, Cameroon.
Judy SakanariDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Sara LustigmanNew York Blood Center, Lindsley F. Kimball Research Institute, New York City, NY, USA.
Fidelis Cho-NgwaANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea, Cameroon. fidelis.cho@ubuea.cm.
University of Buea · CMUniversity of Bamenda · CMNew York Blood Center · USUniversity of California, San Francisco · US

Funding

Bill and Melinda Gates Foundation OPP1098475
6 · The paper itself

Abstract

Onchocerciasis is a devastating skin and eye disease that afflicts about 21 million people, most of whom live in sub-Saharan Africa. Its control with the microfilaricidal drug ivermectin is limited, thus necessitating the development of preclinical animal models to aid in the discovery of a macrofilaricide. Previously, we found that Onchocerca ochengi (the closest relative of the human O. volvulus) worm masses survive better in hamsters than in gerbils. The aim of this study was to compare the survival of O. ochengi adult male worms and their susceptibility to flubendazole (FBZ, a macrofilaricide) in gerbils and hamsters. The animals were intraperitoneally implanted with O. ochengi male worms, treated with FBZ, and sacrificed 35 days post-implantation. Unlike gerbils which had some worms moving freely in the peritoneum and some in newly formed nodules (neo-nodules), all the worms in the hamsters were found in neo-nodules. FBZ significantly decreased worm burden, motility, and viability in gerbils whereas it had no significant effect in hamsters. These results highlight a major difference in how O. ochengi adult male worms are sustained and affected by FBZ in gerbils compared to hamsters. Understanding the difference between these two models is important in the development of effective macrofilaricides for onchocerciasis.

Indexed as

OnchocercaOnchocerciasisAdultAnimalsCricetinaeGerbillinaeHumansMaleMebendazoleflubendazoleMebendazoleAnimal modelsFlubendazoleGerbilHamsterMacrofilariaeOnchocerciasis

Identifiers

PMID38634933
OpenAlexW4394918688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.